Enhanced Anti-Tumor Activity of Cetuximab-Modified Nanostructured Lipid Carriers Loaded with Para-Quinone Methide Derivative p-QM-1h
International Journal of Molecular Sciences · 20.04.2026 · 27 (8) · 3674
DOI: 10.3390/ijms27083674 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.04.2026. Verfasst von Xuanze Lyu und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, Shandong Key Laboratory of Applied Technology for Protein and Peptide Drugs…. Hauptthemen laut MEDLINE: Cetuximab, Drug Carriers, Lipids, Nanostructures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shandong Provincial Natural Science Foundation, the Research Fund of Liaocheng University, Research Fund of Liaocheng University.
Abstract (Originalsprache)
Cancer poses a serious threat to human life and health, and the number of new cancer and death cases worldwide is substantial, of which breast cancer is the most common among women. p-QM-1h is an organic small molecule with excellent anti-cancer activity, but it has low solubility and requires a high dosage, and it is not a targeted anti-tumor drug. In this study, p-QM-1h was loaded into a nanostructured lipid carrier (NLC) using the thin-film dispersion method to construct p-QM-1h-NLC, and its surface was modified with cetuximab (CTX) to construct CTX-p-QM-1h-NLC, which was tested for activity in 4T1 cells and tumor-bearing mice. The construction of CTX-p-QM-1h-NLC used Miglyol 812N as a liquid lipid, which effectively improved the solubility and encapsulation efficiency of p-QM-1h. Nanoparticles were uniform, well dispersed, and had good stability, and the CTX modification of p-QM-1h-NLC exhibited high connection efficiency and ensured antibody integrity. CTX-p-QM-1h-NLC exhibited effective anti-tumor activity in both 4T1 cells and tumor-bearing mice. The construction of CTX-p-QM-1h-NLC effectively improved the solubility of p-QM-1h, enhanced its therapeutic efficacy and reduced its drug dosage. It also had a certain targeting ability, increasing drug aggregation in tumor tissues. Flow cytometry and Western blot results showed that CTX-p-QM-1h-NLC could effectively inhibit the expression of TrxR and increase the expression of Bax and caspase 3 in vivo, which was consistent with the increase in ROS levels and the induction of apoptosis in 4T1 cells. These results indicated that the construction of CTX-p-QM-1h-NLC is worthy of further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, Shandong Key Laboratory of Applied Technology for Protein and Peptide Drugs, School of Pharmaceutical Sciences and Food Engineering, Liaocheng Un…
Förderung
- Shandong Provincial Natural Science Foundation
- the Research Fund of Liaocheng University
- Research Fund of Liaocheng University
Zitieren
APA
Lyu, X., Liu, M., Li, H., Cui, J., Yang, J., & Liu, G. (2026). Enhanced Anti-Tumor Activity of Cetuximab-Modified Nanostructured Lipid Carriers Loaded with Para-Quinone Methide Derivative p-QM-1h. International Journal of Molecular Sciences, 27(8), 3674. https://doi.org/10.3390/ijms27083674
Vancouver
Lyu X, Liu M, Li H, Cui J, Yang J, Liu G. Enhanced Anti-Tumor Activity of Cetuximab-Modified Nanostructured Lipid Carriers Loaded with Para-Quinone Methide Derivative p-QM-1h. International Journal of Molecular Sciences. 2026;27(8):3674. doi:10.3390/ijms27083674
BibTeX
@article{Lyu2026,
author = {Lyu, Xuanze and Liu, Meijia and Li, Hanqing and Cui, Junyi and Yang, Jie and Liu, Guoyun},
title = {Enhanced Anti-Tumor Activity of Cetuximab-Modified Nanostructured Lipid Carriers Loaded with Para-Quinone Methide Derivative p-QM-1h},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {8},
pages = {3674},
doi = {10.3390/ijms27083674}
}
EUVIMED